AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 19556425
Drug: Immunotherapy-treated patients
RxNorm normalized name: trimethylsilyl treated diimethiconol-trimethylsiloxysilicate crosspolymer (45-55 WW)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunotherapy-treated patients (28 patients)
Trial: 19556425
Drug: Decrease in
RxNorm normalized name: Titanium Dioxide 7.2 g in 100 mL / Zinc Oxide 4 g in 100 mL TOPICAL LIQUID [Decree Daily Shield Broad Spectrum SPF 30 Sunscreen]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Decrease in WT1 transcripts after first immunotherapy dose
Trial: 19562254
Drug: Erlotinib plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erlotinib plus sirolimus (150 mg and 5 mg for patients not on concurrent CYP3A-inducing anti-epileptics; 450 mg and 10 mg for patients on EIAEDS)
Trial: 19565495
Drug: Anti-TNF monoclonal
RxNorm normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Anti-TNF monoclonal antibody therapy (infliximab, adalimumab)
Trial: 19565495
Drug: Anti-TNF monoclonal
RxNorm normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Anti-TNF monoclonal antibody therapy (etanercept)
Trial: 19569973
Drug: 90 microg
RxNorm normalized name: Linaclotide 290 microgram oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 90 microg H5N1 A/Vietnam/1203/04 vaccine
Trial: 19569973
Drug: 120 microg
RxNorm normalized name: Betamethasone 120 microgram/mL oral solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120 microg H5N1 A/Vietnam/1203/04 vaccine
Trial: 19569973
Drug: 180 microg
RxNorm normalized name: Pramipexole (as pramipexole dihydrochloride) 180 microgram oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 180 microg H5N1 A/Vietnam/1203/04 vaccine
Trial: 19573495
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg oral lorazepam
Trial: 19576329
Drug: Guideline-recommended therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guideline-recommended therapies (angiotensin-converting enzyme inhibitor/angiotensin receptor blocker and beta-blocker use)
Trial: 19576329
Drug: All guideline-recommended
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All guideline-recommended cardiac medications prescribed at discharge
Trial: 19581810
Drug: Optimized treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimized treatment with oral lansoprazole
Trial: 19584400
Drug: ABVE-PC (doxorubicin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABVE-PC (doxorubicin, bleomycin, vincristine, etoposide, prednisone, cyclophosphamide) administered every 21 days
Trial: 19586800
Drug: Sunitinib (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunitinib (50 mg/day for 4 weeks, followed by 2 weeks off treatment)
Trial: 19586800
Drug: Sunitinib (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunitinib (50 mg/day)
Trial: 19587341
Drug: Intraarticular delivery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraarticular delivery of a TNF-alpha antagonist via an AAV type 2 delivery system
Trial: 19587341
Drug: Concurrent anti-TNF-alpha
RxNorm normalized name: anti-interleukin-1.alpha. immunoglobulin G rabbit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent anti-TNF-alpha therapy and other immunosuppressive therapy
Trial: 19587528
Drug: Mtb72F/AS02A vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mtb72F/AS02A vaccine (3 doses according to a 0-1-2 months schedule)
Trial: 19587528
Drug: Mtb72F/AS02A vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mtb72F/AS02A vaccine
Trial: 19594547
Drug: Oral fludarabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral fludarabine in combination with rituximab (375 mg/m² rituximab on day 1, 40 mg/m² oral fludarabine once daily on days 1-5 every 28 days for up to six cycles)
Trial: 19594547
Drug: Oral fludarabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral fludarabine in combination with rituximab
Trial: 19594946
Drug: Steroid-sensitive (SS)
RxNorm normalized name: Fluorimax Sensitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid-sensitive (SS) patients
Trial: 19597050
Drug: Systematic clinical
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systematic clinical testing including cardiac magnetic resonance imaging, signal-averaged ECG, exercise testing, drug challenge, and selective electrophysiological testing.
Trial: 19601706
Drug: Intra-articular Hylan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular Hylan G-F 20 injections
Trial: 19604722
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy (cisplatin with docetaxel) followed by accelerated concomitant boost radiotherapy (44 Gy in 22 fractions) and definitive surgery
Trial: 19605490
Drug: Modified vaccinia
RxNorm normalized name: Modified vaccinia ankara
DrugBank: Modified vaccinia ankara (DB15483)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified vaccinia virus Ankara/fowlpox virus-based HIV-1 vaccines
Trial: 19608747
Drug: All preparative
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All preparative regimens with CD34(+) cell doses exceeding 4.5 x 10(6)/kg
Trial: 19608747
Drug: Higher CD34(+)
RxNorm normalized name: Autologous CD34+ cells encoding βA-T87Q-Globin gene
DrugBank: Betibeglogene autotemcel (DB16900)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher CD34(+) cell doses
Trial: 19615940
Drug: Sunitinib 50
RxNorm normalized name: sunitinib 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunitinib 50 mg orally once daily on schedule 4-2 (4 weeks on treatment, 2 weeks off)
Trial: 19616281
Drug: Erlotinib 150
RxNorm normalized name: erlotinib 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erlotinib 150 mg daily until disease progression
Trial: 19620489
Drug: 32 or
RxNorm normalized name: Darvon Compound 32 Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 32 or 36 Gy in 4-Gy fractions, given twice daily (36 Gy cohort with pure photons)
Trial: 19620516
Drug: Acetyl-L-carnitine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetyl-L-carnitine (1 g twice daily) for 24 weeks
Trial: 19624460
Drug: Dalteparin injected
RxNorm normalized name: dalteparin Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dalteparin injected subcutaneously (s.c.) twice daily at a median dose of 90 (73-106) units kg(-1) per 12 h
Trial: 19624460
Drug: Dalteparin injected
RxNorm normalized name: dalteparin Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dalteparin injected subcutaneously (s.c.) twice daily
Trial: 19625715
Drug: Vi vaccine
RxNorm normalized name: TYPHIM Vi VACCINE INJ SYRINGE 0.5ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vi vaccine (children aged 2-5 years)
Trial: 19625715
Drug: Vi vaccine
RxNorm normalized name: TYPHIM Vi VACCINE INJ SYRINGE 0.5ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vi vaccine (unvaccinated neighbors)
Trial: 19625715
Drug: Vi vaccine
RxNorm normalized name: TYPHIM Vi VACCINE INJ SYRINGE 0.5ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vi vaccine (overall residents in clusters)
Trial: 19628656
Drug: Losartan (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan (50 mg/day) for 18 months
Trial: 19629020
Drug: Pharmaceutical antidepressants
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pharmaceutical antidepressants
Trial: 19630971
Drug: Erythropoietin (epoietin-beta)
RxNorm normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythropoietin (epoietin-beta) at high doses (1,500 U/kg/day for three days) combined with quinine
Trial: 19630971
Drug: Erythropoietin (epoietin-beta)
RxNorm normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythropoietin (epoietin-beta) at high doses combined with quinine
Trial: 19635928
Drug: Inhalation of
RxNorm normalized name: Ocean brand of sodium chloride Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation of acid sphingomyelinase inhibitors (amitriptyline, trimipramine, desipramine, chlorprothixene, fluoxetine, amlodipine, sertraline)
Trial: 19636002
Drug: Bevacizumab, capecitabine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab, capecitabine, and radiation (50.4 Gy per 28 fractions, capecitabine 825 mg/m² orally twice daily on days of radiation, bevacizumab 5 mg/kg on days 1, 15, and 29, followed by maintenance gemcitabine 1 g/m² weekly for 3 weeks and bevacizumab 5 mg/kg every 2 weeks)
Trial: 19636010
Drug: Dacetuzumab (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dacetuzumab (2 mg/kg weekly for 4 weeks, with dose escalation up to 8 mg/kg)
Trial: 19638905
Drug: Subcutaneous mastectomy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous mastectomy with nipple-areola skin conservation
Trial: 19641325
Drug: Rosiglitazone, 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosiglitazone, 4 mg daily for 6 months
Trial: 19643318
Drug: MRI at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MRI at 1.5-T with specific absorption rate limited to 2 W/kg; ICDs reprogrammed pre-MRI
Trial: 19646269
Drug: Final version
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Final version of the quantitative survey administered to all registered call takers
Trial: 19648219
Drug: Bupropion and
RxNorm normalized name: bupropion and naltrexone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupropion and group therapy for 2 months
Trial: 19648970
Drug: Topotecan at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topotecan at 4.5 mg/m(2)/d combined with CY 1.5 g/m(2)/d and carboplatin 200 mg/m(2)/d
Trial: 19648970
Drug: Topotecan at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topotecan at 6.0 mg/m(2)/d combined with CY 1.5 g/m(2)/d and carboplatin 200 mg/m(2)/d
Trial: 19648970
Drug: Topotecan (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topotecan (various doses)
Trial: 19651065
Drug: Topical recombinant
RxNorm normalized name: thrombin topical recombinant 5000 intl units topical powder for reconstitution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical recombinant human thrombin (rThrombin) applied during surgical procedure (day 1)
Trial: 19651065
Drug: Topical recombinant
RxNorm normalized name: thrombin topical recombinant 5000 intl units topical powder for reconstitution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical recombinant human thrombin (rThrombin)
Trial: 19652055
Drug: Sorafenib 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sorafenib 400 mg orally twice daily until tumor progression or unacceptable toxicity
Trial: 19652067
Drug: Pralatrexate at
RxNorm normalized name: Pralatrexate
DrugBank: Pralatrexate (DB06813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pralatrexate at a dose of 30 mg/m(2) weekly for 6 weeks every 7 weeks (MTD established in phase I/II study)
Trial: 19652067
Drug: Pralatrexate at
RxNorm normalized name: Pralatrexate
DrugBank: Pralatrexate (DB06813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pralatrexate at a dose of 135 mg/m(2) every other week
Trial: 19652630
Drug: Quadrivalent HPV
RxNorm normalized name: HPV, quadrivalent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quadrivalent HPV vaccine (Type 6/11/16/18)
Trial: 19663708
Drug: HBV vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HBV vaccine booster
Trial: 19664754
Drug: High-dose intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose intravenous daclizumab (8 mg/kg at baseline, 4 mg/kg at week 2, 2 mg/kg every 4 weeks for 52 weeks)
Trial: 19664754
Drug: High-dose intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose intravenous daclizumab
Trial: 19666119
Drug: ET(A) antagonist
RxNorm normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: ET(A) antagonist BMS187824 (5 mg/kg, i.v.) followed by IRL-1620 (5 microg/kg, i.v.)
Trial: 19671016
Drug: Parenteral procaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral procaine benzyl penicillin and an aminoglycoside
Trial: 19671733
Drug: Oleandrin treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oleandrin treatment
Trial: 19675988
Drug: Powered knee
RxNorm normalized name: Bos taurus knee joint preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Powered knee prosthesis with two series-elastic actuators in an agonist-antagonist arrangement
Trial: 19679883
Drug: Subcutaneous rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subcutaneous rituximab (20 mg, thrice weekly for up to 12 weeks)
Trial: 19679883
Drug: Intravenous rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenous rituximab (thrice-weekly, fractionated-dose)
Trial: 19687399
Drug: Photodynamic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photodynamic therapy with porfimer sodium (2 mg/kg, injected intravenously 48 hours before treatment) and light at 630 nm (50 J/cm² for dysplasia and CIS, 75 J/cm² for carcinoma)
Trial: 19687399
Drug: Photodynamic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photodynamic therapy with porfimer sodium
Trial: 19689789
Drug: Neoadjuvant anti-estrogen
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant anti-estrogen therapy (Tamoxifen for premenopausal women, Letrozole for postmenopausal women)
Trial: 19689789
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (patients who did not undergo preoperative anti-estrogenic treatment)
Trial: 19690058
Drug: Capecitabine 1000
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine 1000 mg/m(2) b.i.d. for 2 weeks followed by capecitabine 575-650 mg/m(2) b.i.d. and cisplatin 20-25 mg/m(2) i.v. weekly during chemoradiotherapy
Trial: 19696651
Drug: Antiretroviral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiretroviral therapy in acute HIV-1 infection
Trial: 19696651
Drug: Antiretroviral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiretroviral therapy in recent HIV-1 infection
Trial: 19696651
Drug: Baseline viral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline viral load <100,000/ml
Trial: 19696651
Drug: Baseline viral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline viral load >100,000/ml
Trial: 19697416
Drug: Preservative-free (PF)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preservative-free (PF) hepatitis B vaccine
Trial: 19697416
Drug: Preservative-containing (PC)
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preservative-containing (PC) hepatitis B vaccine
Trial: 19697416
Drug: Low-preservative (LP)
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-preservative (LP) hepatitis B vaccine
Trial: 19698816
Drug: Levonorgestrel (LNG)
RxNorm normalized name: Levonorgestrel
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Levonorgestrel (LNG) 90 mcg/ethinyl estradiol (EE) 20 mcg, taken continuously for three 28-day intervals.
Trial: 19700662
Drug: Cytotoxic T
RxNorm normalized name: Cytotoxic T-lymphocyte proteinase 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cytotoxic T lymphocyte (CTL) therapy with specificity for Epstein-Barr virus (EBV) and adenovirus (5 x 10(6)-1.35 x 10(8) cells/m(2))
Trial: 19700662
Drug: Cytotoxic T
RxNorm normalized name: Cytotoxic T-lymphocyte proteinase 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cytotoxic T lymphocyte (CTL) therapy with specificity for adenovirus
Trial: 19703299
Drug: Atomoxetine (0.5-1.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atomoxetine (0.5-1.2 mg/kg/day)
Trial: 19712979
Drug: Escitalopram, 10
RxNorm normalized name: Escitalopram, 10 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escitalopram, 10 mg for 49 days
Trial: 19712979
Drug: Escitalopram, 10
RxNorm normalized name: Escitalopram, 10 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escitalopram, 10 mg after 1 week
Trial: 19712979
Drug: Serum drug
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum drug levels and genetic polymorphisms (5HTTLPR and 5HT2a)
Trial: 19713456
Drug: Bortezomib (1.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bortezomib (1.3 mg/m2)
Trial: 19714615
Drug: Belimumab (1,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Belimumab (1, 4, 10 mg/kg) plus standard of care therapy (SOC)
Trial: 19714615
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus standard of care therapy (SOC)
Trial: 19718477
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of PTX3 and BNP
Trial: 19720904
Drug: Lenalidomide 10
RxNorm normalized name: lenalidomide 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lenalidomide 10 mg/d (5 mg/d if baseline platelet count < 100 x 10(9)/L) on days 1 through 21 of a 28-day cycle for six cycles, plus prednisone 30 mg/d during cycle 1, 15 mg/d during cycle 2, and 15 mg/d every other day during cycle 3.
Trial: 19720904
Drug: Lenalidomide and
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lenalidomide and prednisone combination therapy
Trial: 19720915
Drug: Paclitaxel (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel (80 mg/m(2) once weekly during postoperative weeks 2, 3, and 4) followed by concurrent Paclitaxel (30 mg/m(2)) and Cisplatin (20 mg/m(2)) once weekly during the last 3 weeks of RT (60 Gy over 6 weeks).
Trial: 19720915
Drug: Paclitaxel and
RxNorm normalized name: paclitaxel and encequidar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel and Cisplatin with radiation therapy (RT).
Trial: 19720923
Drug: Concurrent trastuzumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent trastuzumab and HER2/neu-specific vaccination
Trial: 19721480
Drug: Pegylated interferon
RxNorm normalized name: Pegylated interferon alfa-2a
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pegylated interferon (180 microg weekly) and ribavirin (800 mg daily) for 14 weeks
Trial: 19723786
Drug: CBT monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CBT monotherapy
Trial: 19725960
Drug: pegylated liposomal
RxNorm normalized name: doxorubicin HCl pegylated liposomal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pegylated liposomal doxorubicin (20 mg/m2) and prolonged Temozolomide (75 mg/m2 during radiotherapy, 150-200 mg/m2 on days 1-5 of each 28-day cycle) with radiotherapy (60 Gy)
Trial: 19725960
Drug: pegylated liposomal
RxNorm normalized name: doxorubicin HCl pegylated liposomal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pegylated liposomal doxorubicin (20 mg/m2) and prolonged Temozolomide with radiotherapy
Trial: 19726437
Drug: Thrombectomy in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrombectomy in patients treated with IIb/IIIa-inhibitors
Trial: 19726763
Drug: GDC-0449 (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GDC-0449 (150 mg per day)
Trial: 19726763
Drug: GDC-0449 (270
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GDC-0449 (270 mg per day)
Trial: 19726763
Drug: GDC-0449 (540
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GDC-0449 (540 mg per day)
Trial: 19727007
Drug: Direct Renin
RxNorm normalized name: DIRECT RENIN INHIBITOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct Renin Inhibitors (DRIs)
Trial: 19727007
Drug: Direct Renin
RxNorm normalized name: DIRECT RENIN INHIBITOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct Renin Inhibitors (DRIs) added to optimal heart failure treatment
Trial: 19727007
Drug: Early generation
RxNorm normalized name: regenerated cellulose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early generation Direct Renin Inhibitors (DRIs)
Trial: 19727007
Drug: Recent Direct
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recent Direct Renin Inhibitors (DRIs)
Trial: 19728876
Drug: Volume expansion
RxNorm normalized name: VOLUME EXPANDERS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Volume expansion (VE) with 500 mL of synthetic colloid
Trial: 19731330
Drug: Hydroxyurea (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxyurea (20 mg/kg/day for 2 years)
Trial: 19738014
Drug: Intravenous ganciclovir
RxNorm normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous ganciclovir at 5 mg/kg of body weight for 5 days, followed by oral valganciclovir at 900 mg for 16 days, both twice daily with dose adjustment for renal function.
Trial: 19740906
Drug: Tumour necrosis
RxNorm normalized name: Tumour necrosis factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tumour necrosis factor alpha inhibitors (TNFalpha) - infliximab (n=41), etanercept (n=13), adalimumab (n=6)